In NSCLC, primary resistance mechanism of ALK-fusion positive tumours has been mostly secondary mutations within the kinase domain of EML4-ALK, either when compromising drug binding (L1196M, G1269A) or when affecting enzyme conformation and activity (C1156Y, I1171T) [11,38]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.